Italy

NanoPhoria Bioscience raises record-breaking €83.5M Series A to advance heart failure therapy and expand nano-delivery platform
NanoPhoria Bioscience, a next-generation biotech developing inhalable cardiovascular therapies, has raised €83.5 million in a landmark Series A round — the largest ever for an Italian biotech.
In a significant development for the biotech industry, SQIM (formerly known as Mogu Srl), an Italian company at the forefront of material innovation, has successfully secured €11 million in a Series A funding round. This substantial investment, led by CDP Venture Capital, marks a pivotal moment in the company's journey